The letter is dated June 8, 2026, reference MARCS-CMS 728279, from the FDA's Office of Compounding Quality and Compliance to Eden Health International Inc. (read November 15, 2026). It makes two specific findings about Eden's website:
| What the FDA found | Why it matters |
|---|---|
| Pictures of the compounded semaglutide and tirzepatide products showed labels bearing the "Eden" name, which the FDA said "suggest[s] Eden is the compounder of those drugs when in fact it is not." | A patient should be able to tell which pharmacy made the product. The FDA asked Eden to identify the entities that produce the products and to supply representative labeling. |
| The site described its pharmacies as "FDA-licensed 503(a) outsourcing facilities." The FDA stated that compounding facilities "are not 'FDA-approved' or 'FDA-licensed' entities." | No compounding pharmacy or outsourcing facility holds FDA approval or an FDA licence; the phrase overstates the oversight a buyer is getting. |
The FDA classed both as misbranding under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act and asked for a written response within 15 business days with corrective and preventive steps. altRx received a letter dated the same day.
Three things follow, and they pull in different directions. First, the letter contains no finding about the medication itself: no test result, no adverse-event report, no quality defect. Treating it as proof that Eden's products are unsafe would be wrong. Second, it is not insignificant: a warning letter is the FDA's formal notice that a company's conduct violates the law, and the two points it raises, who made the drug and how its oversight was described, are exactly the questions a compounded-GLP-1 buyer should be asking. Third, the letter is explicit that compounded products "have not been evaluated by FDA for safety, effectiveness, or quality before marketing." That applies to every compounded provider we rank, Eden included. As of November 15, 2026 we have not found a published response from Eden or an FDA close-out letter; we will update this section when either appears.



